Cell and Gene Therapy Bio-manufacturing Market Key Players Analysis - Getinge AB, Infors AG, Lonza Group Ltd, Merck KGaA, Miltenyi Biotec B.V. & Co. K.G., PIERRE GUERIN.

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Cell and Gene Therapy Bio-manufacturing Market Size, Share & Trends Analysis Report By Product Type (Consumables, Equipment, And Software Solutions), Usage (Commercial-Stage Manufacturing And Research-Stage Manufacturing), Application (Upstream Processing, Harvesting, And Downstream Processing), And End-User (Life Science Companies, Contract Research Organizations (Cros), Contract Manufacturing Organizations (CMOs), And Cell Banks)- Market Outlook And Industry Analysis 2031"

The global cell and gene therapy bio-manufacturing market is estimated to reach over 40.2 billion by the year 2031, exhibiting a CAGR of 11.4% during the forecast period.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1692

The global cell and gene therapy bio-manufacturing market is poised for significant growth, driven by an increase in the number of approved therapies and the rising demand for enhanced infrastructure. Additionally, the expanding range of target indications for cell and gene therapies is fueling the need for large-scale bio-manufacturing capabilities. Key factors contributing to this market expansion include substantial investments from government entities and leading industry players. Over the past decade, approximately USD 2.3 billion has been invested in gene therapy companies, signaling strong interest from major pharmaceutical and biotechnology firms in advancing gene therapy technologies. Furthermore, prominent contract development and manufacturing organizations (CDMOs/CMOs) and in-house manufacturers are recognizing gene and cell therapy as a critical investment area. The pharmaceutical and biotechnology sectors continue to invest heavily in research and development in this field. According to the US Food and Drug Administration (USFDA), there has been a marked increase in cell and gene therapy products entering early-stage development. As a result of these factors, the market is expected to experience robust growth throughout the forecast period.

List of Prominent Players in the Cell and Gene Therapy Bio-manufacturing Market:
• Becton, Dickinson and Company
• Endress+Hauser Group Services AG (Analytik Jena GmbH)
• Danaher Corporation
• Bio-Rad Laboratories, Inc.
• Bio-Techne Corporation
• General Electric Company (G.E. Healthcare)
• Getinge AB
• Infors AG
• Lonza Group Ltd
• Merck KGaA
• Miltenyi Biotec B.V. & Co. KG
• PIERRE GUERIN
• Sartorius AG (Sartorius Stedim Biotech S.A.)
• Thermo Fisher Scientific Inc.
• WuXi AppTec

Market Dynamics:
Drivers-
The increasing incidence of cancer and other targeted diseases, coupled with rising research and development investments from pharmaceutical companies, is driving the expansion of the market. According to the latest updates from the International Agency for Research on Cancer (IARC) in GLOBOCAN 2020, the global cancer burden has reached 19.3 million cases. This growing prevalence is expected to heighten the demand for gene therapy, further supporting market growth. Additionally, a study published in the Journal of Orthopedic Surgery and Research in October 2021, titled "The Worldwide Prevalence of Osteoporosis in the World: A Comprehensive Systematic Analysis and Meta-analysis," reports that the global prevalence of osteoporosis stands at 18.3%. Stem cell therapies for osteoporosis hold the potential to reduce fracture risk. As the prevalence of orthopedic diseases continues to rise, the demand for cell and gene therapy manufacturing services is anticipated to increase correspondingly.

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-01

Challenges:
One of the primary challenges facing the market is the high cost of treatments, which imposes significant financial burdens on patients, healthcare providers, and payers, thereby limiting market growth. For example, in May 2022, the US FDA approved chimeric antigen receptor T-cell therapy for pediatric and young adult patients with refractory or relapsed B-cell precursor acute lymphoblastic leukemia, with a single infusion costing approximately USD 475,000. As a result, the high cost of such therapies has led to limited adoption, constraining the overall growth of the market.

Regional Trends:
The North American market for cell and gene therapy bio-manufacturing is expected to capture a significant share of revenue and is projected to expand at an accelerated compound annual growth rate (CAGR) in the near future. This growth is driven by the increasing prevalence and incidence of infectious diseases in the region, coupled with the aging population. Gene therapies are widely utilized in diagnostics, therapeutics, drug development, and research for oncology and other clinical conditions, with the United States being one of the most affected countries. As a result, demand for these therapies is expected to be particularly strong in North America, where the patient population is growing at a faster pace compared to other regions.

Recent Developments:
• In January 2022, AllogeneTherapeutics Inc and AntionBiosciences Inc. formed an exclusive collaboration and global license agreement for Antion's miRNA technology (miCAR) to advance multiplex gene silencing as an additional tool in the development of next-generation allogeneic CAR T products.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/1692

Segmentation of Cell and Gene Therapy Bio-manufacturing Market-
By Product Type-
• Consumables
o Culture Supplements
 Media
 Serum
 Macronutrients
o Single-Use Liquids
o Cell Culture Reagents
o Cell Quantification Kits
• Equipment
o Bioreactors/Fermenters
 Continuous Bioreactors
 Single-Use Bioreactors
o Mixing Systems
o Cell Counters
o Cell Sorters
o Centrifuges
o Incubators
o Biosafety Cabinets
o Freezers
o PCR Systems
o Transfection Systems
o Storage Tanks
o Others
• Software Solutions
By Usage-
• Commercial Stage Manufacturing
• Research Stage Manufacturing
By Application-
• Upstream Processing
o Formulation and Hydration
o Cell Culture Processing
• Harvesting
• Downstream Processing
o Separation and Filtration
o Fill and Finish Operations
By End-User-
• Life Science Companies
o Equipment
o Consumables
o Software Solutions
• Contract Research Organizations (CROs)
o Equipment
o Consumables
o Software Solutions
• Contract Manufacturing Organizations (CMOs)
o Equipment
o Consumables
o Software Solutions
• Cell Banks
o Equipment
o Consumables
o Software Solutions
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/cell-and-gene-therapy-bio-manufacturing-market/1692

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.